Key Takeaways:
A class-action lawsuit has been filed against Medpace Holdings Inc. (NASDAQ: MEDP) after the clinical research firm allegedly misled investors about its business health, leading to a stock drop of nearly 16 percent.
The lawsuit alleges that Medpace and its top executives made false or misleading statements by consistently overselling a key performance metric. The complaint, filed by Robbins Geller Rudman & Dowd LLP, claims the company "knew or recklessly disregarded the impact that cancellations have on Medpace's book-to-bill ratio."
The complaint centers on the company’s fourth-quarter 2025 guidance. Executives projected a book-to-bill ratio of 1.15, reassuring investors that order cancellations were "very well behaved." However, on February 9, 2026, Medpace released earnings revealing a ratio of just 1.04. The news caused the stock to fall from $530.35 to $446.05 per share in one day.
The fallout for Medpace has since worsened. On April 23, 2026, reports emerged that the company’s book-to-bill ratio had fallen further to 0.88 for the first quarter of 2026 and that company President Jesse Geiger intended to resign. This news triggered a second, more severe stock decline of approximately 23 percent. Multiple law firms have now issued alerts for investors.
The decline puts the stock at its lowest since the start of the year, with the ongoing legal proceedings representing a significant headwind. Investors who purchased Medpace common stock between April 22, 2025, and February 9, 2026, have until June 8, 2026, to seek appointment as lead plaintiff in the case.
This article is for informational purposes only and does not constitute investment advice.
